Cleveland Clinic's 2020 Multidisciplinary Head and Neck Cancer Update
To De-intensification in HPV+ Oropharyngeal Cancer: For Induction Chemo Responders, Reduced-Dose IMRT + Concurrent Cetuximab Is Worthy of Further Study in Favorable-Risk Pts
Login to view comments.
Click here to Login
